This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Histone-lysine N-methyltransferase 2A.
From the MLL1/MLL complex, it specifically mediates H3K4me, a particular tag for epigenetic transcriptional activation (PubMed:12453419, PubMed:20677832, PubMed:26886794). Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to acquire whole methyltransferase activity (PubMed:19187761, PubMed:26886794).
Human | |
---|---|
Gene Name: | KMT2A |
Uniprot: | Q03164 |
Entrez: | 4297 |
Belongs to: |
---|
class V-like SAM-binding methyltransferase superfamily |
ALL1; ALL-1MLL/GAS7; CXXC7TET1-MLL; CXXC-type zinc finger protein 7; EC 2.1.1.43; HRXFLJ11783; HTRX; HTRX1MLL-AF4 der(11) fusion protein; KMT2ACDK6/MLL fusion protein; Lysine N-methyltransferase 2A; MLL/GAS7 fusion protein; MLL/GMPS fusion protein; MLL1; MLL1A; myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); Trithorax-like protein; TRX1histone-lysine N-methyltransferase MLL; Zinc finger protein HRX
Mass (kDA):
431.764 kDA
Human | |
---|---|
Location: | 11q23.3 |
Sequence: | 11; NC_000011.10 (118436492..118526832) |
Heart, lung, brain and T- and B-lymphocytes.
Nucleus.; [MLL cleavage product N320]: Nucleus.; [MLL cleavage product C180]: Nucleus. Localizes to a diffuse nuclear pattern when not associated with MLL cleavage product N320.
This article will provide a brief history of Boster Bio Anti–MLL KMT2A Monoclonal Antibody. Learn about the Antibody, its uses in clinical and research, and more! It's time to learn more about this monoclonal anti-body!
Boster Bio Anti–MLLKMT2-A monoclonal Anti-MLL KMT2-A antibody targets MLL–AF4 Fusion Protein, which is expressed as t(4–11) leukemia. This antibody recognizes an immunogen that maps to the residues 720-780 from human myeloid/lymphoid.
The U.S. Food and Drug Administration granted approval for bebtelovimab in treating COVID-19. This drug is approved for use in children and adults with severe cases of the disease. Apart from its effectiveness against COVID–A, bebtelovimab retains activity against COVID–F-related TCM (omicron variant).
If you're curious about Steven Boster's history, you're in the right place. Public records include Steve Boster's current address, past addresses, mobile phone numbers and email addresses, as well as his known relatives. This information can be filtered by age, state, and other criteria. You'll discover many of Steve Boster's fascinating details, including his career trajectory, his hobbies, and more. You'll be happy to know that he was active within a variety of industries.
Steve Boster was born in Joliet (Illinois) on June 6, 1952. He was a manager in the retail sales industry for many years. He was also a veteran of the U.S. Army. He also leaves behind many nieces and nephews.
Tissue science has been around almost as long than man. Through scientific breakthroughs, the analysis of tissues has become more sophisticated. Boster Bio has mastered the art of manufacturing antibodies and immune system supplements using the most advanced technology available. This allows them to process data from Immunohistochemistry and research assays and people's laboratory tests in the most precise way possible.
Antibody-mediated infection is dependent on the Fc receptor II. This method, unlike the endosomal/lysosomal pathways, uses a single complement receptor (CR), cell as a host cell'strophic agents. This method not only allows for antibody-mediated infection but also expands the cell tropism of coronaviruses giving them a broad range trophies.
Antibodies are immunoglobulin molecules. Each molecule has two basic units, a light and a heavy chain. These chains interact with antigens by binding to the paratope. A paratope, in turn, cannot be recognized by an antibody without its antigen partner. Antigen-antibody identification is dependent on the antigen's structure and its three-dimensional (3D), conformation. Modifying any protein with formalin will compromise its conformation, rendering the AR ineffective.
KMT2A is a gene involved in the Ras pathway. The development of leukemia is linked to mutations in this gene, including acute lymphoblastic lymphoma and B-cell Lymphoma. The KMT2A gene marker can be used in a variety clinical settings. Its clinical utility is limited due to the lack a validated molecular diagnostic testing.
The Interfant-06 Study, which involved 439 newborns suffering from KMT2Ar, did not produce conclusive results. MRD levels did NOT differ between IG/TR or KMT2Ar. The MRD levels of 19 patients with KMT2Ar were the same, but there were some differences. The results were similar in ninety-nine percent of cases. Twenty-nine percent of patients had a relapse of the disease during the follow-up period, while only two patients developed a second malignancy.
A B-ALL infant with KMT2A, rearranged nucleoplasmic nuclear cytoplasmicDNA DNA was classified as an ELP-like type. Independent data from pediatric B-ALL revealed that infant lymphoblasts resemble human fetal ELPs, which is the primary difference between the infant and standard-risk B-ALL subtypes. Despite being infants, the cell signal in this subtype is significantly higher than the other B–ALL subtypes.
The KMT2A gene is used to determine the genetic susceptibility and screen patients for minimal residual disease (AML) in acute lymphoblasticleukemia. This marker can also be used to develop targeted therapy for patients with the disease. This marker could be useful in screening for men with abnormal KMT2A genes in leukemia patients. These patients must be resistant to standard therapies, but still have adequate organ function.
The high incidence of KMT2A rearrangements in infant acute lymphoblasticleukemia is associated to poor outcomes. The Interfant-06 protocol evaluated the effectiveness of myeloid and lymphoid-type consolidation in 249 infants with KMT2A-rearranged ALL. Patients with higher MRD at EOI had better outcomes than those with lower MRD.
PMID: 1423624 by Tkachuk D.C., et al. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.
PMID: 8703835 by Nilson I., et al. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias.